by Bernice Lottering – Gene Online –
Regenerative medicine, as a whole, is in a critical position to transform healthcare and confront several critical challenges that threaten its widespread adoption. High costs, complex development processes, and intricate biological mechanisms in therapy manufacturing are major hurdles. Moreover, balancing efficacy, manufacturing consistency, and regulatory compliance adds further obstacles. In response, the Forum for Innovative Regenerative Medicine (FIRM) is actively addressing these issues. By fostering collaboration across diverse industries, promoting ethical practices, and navigating Japan’s evolving regulatory landscape, FIRM is ensuring that patient-centered care drives the future of regenerative medicine. Consequently, the industry is seeing a shift towards a more sustainable and ethically grounded approach.
